Alzheimer’s Drug PRI-002 Receives EMA Approval for Phase II Trial
The Alzheimer’s drug candidate PRI-002 is entering the next clinical trial phase: the European Medicines Agency (EMA) has granted approval to conduct a phase II clinical trial. This is the first time that the drug candidate will be tested on a larger number of Alzheimer’s patients. The drug was developed at Forschungszentrum Jülich and Heinrich Heine University Düsseldorf (HHU). In September 2017, Priavoid GmbH was founded as a spin-off of Forschungszentrum Jülich with the aim of marketing the drug. (Source: Forschungszentrum Jülich – Presse releases)
“After decades of setbacks in drug development, there have been some recent positive developments. We can’t wait to start the study,” explains Prof. Dieter Willbold, co-founder of Priavoid GmbH and Director at the Jülich Institute of Structural Biochemistry from Helmholtz Information, as well as a Professor of Physical Biology at HHU.
The goal of the study is to demonstrate the efficacy of PRI-002 in patients at an early stage of Alzheimer’s disease. For this purpose, the drug candidate will be tested in a placebo-controlled Phase II study involving 270 patients in initially six European countries. The safety of PRI-002 for healthy volunteers and patients has already been successfully demonstrated in three Phase I studies conducted in recent years.
The Phase II study, named PRImus-AD, is sponsored by the company PRInnovation in close collaboration with Priavoid and is funded by the Federal Agency for Jump Innovations (SPRIND) from the funds of the Federal Ministry of Education and Research.
The drug candidate PRI-002 targets small soluble protein aggregates – the so-called amyloid-beta oligomers – which are considered important drivers of the disease process in Alzheimer’s. PRI-002 is capable of directly dissolving these toxic amyloid aggregates into their harmless building blocks (‘monomers’) without the involvement of the immune system, thereby rendering them harmless. “It is, therefore, a purely physical mechanism of action,” explains Dieter Willbold. “This sets PRI-002 apart fundamentally from drug candidates based on antibodies, which are currently seeking drug approval.”
Great hopes are pinned on the now-approved Phase II study, as Germany alone has approximately 1.1 million Alzheimer’s patients for whom, to date, no effective, disease-modifying, and safe medications have been approved.
The results of this study are expected in 2026. The aim is to seamlessly transition into a corresponding Phase III approval study thereafter.
FZJ/A. Stettien, 21.11.2023
The original press release can be found at:
Alzheimer’s Drug PRI-002 Receives EMA Approval for Phase II Trial
Localization in the Helmholtz Research Field Information:
Helmholtz Information, Programm 2: Natural, Artificial and Cognitive Information Processing, Topic 4: Molecular and Celullar Information
Further Information:
Also, visit our official website and follow us on our LinkedIn channel of Helmholtz Information to receive up-to-date information, event announcements, and insights into our research activities in Helmholtz Information.
Contact:
Prof. Dr. Dieter Willbold
Institute of Biological Information processing (IBI)
Structural Biochemistry (IBI-7)
Forschungszentrum Jülich
Phone: +49 2461 61-2100
E-Mail: d.willbold@fz-juelich.de
Contact for this press release:
Dipl. Biol. Annette Stettien
Head of External Communication
Forschungszentrum Jülich
Phone: +49 2461 61-2388
E-Mail: a.stettien@fz-juelich.de
